Integrating the Latest Data Into Best Practices for Patients With HER2+ Breast Cancer

Nusayba Bagegni, MD, details ongoing research and possibilities for the treatment landscape in the future, which includes investigating escalating approaches through more research in clinical trials.

Related Keywords

Nusayba Bagegni ,Washington University ,Washington University School Of Medicine ,Antonio Breast Cancer Symposium ,Breast Cancer ,Washington University School ,Her2 Positive And Low Breast Cancer ,2022 San Antonio Breast Cancer Symposium ,Phase 2 Apt Trial ,Phase 2 Atempt Trial ,Fam Trastuzumab Deruxtecan Nxki ,